The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B who meet certain requirements.

The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B who meet certain requirements.

The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S.

The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B who meet certain requirements.

The treatment will be available by prescription to eligible patients this quarter, a Pfizer spokesperson told CNBC. It has a hefty $3.5 million price tag, before insurance and other rebates, the spokesperson added, making it by far one of the most expensive drugs in the U.S.

  • paysrenttobirds@sh.itjust.worksEnglish
    0·
    7 months ago

    BEQVEZ is a one-time treatment that is designed to enable people living with hemophilia B to produce FIX themselves rather than the current standard of care, which requires regular intravenous infusions of FIX that are often administered multiple times a week or multiple times a month.1,2

    A 2021 study found that the cost for an adult’s lifetime treatmentTrusted Source of moderately severe to severe hemophilia B averages $22,987,483 million for preventive FIX treatment and $20,971,826 for on-demand FIX treatment. –https://www.healthline.com/health/hemophilia-treatment#costs

    • IamtheMorgz@lemmy.worldEnglish
      0·
      7 months ago

      Ooh, I think I remember reading somewhere that these patients have to be moved around insurance pools in the US just to keep the insurance industry working, lol. Because they’re so expensive. I guess 3.5 is less than 20.